ATE315395T1 - Pharmazeutische zusammensetzungen, die faropenem natrium und eine diamineacetat verbindung zur verbesserung der magen-darm trakt absorption enthalten - Google Patents

Pharmazeutische zusammensetzungen, die faropenem natrium und eine diamineacetat verbindung zur verbesserung der magen-darm trakt absorption enthalten

Info

Publication number
ATE315395T1
ATE315395T1 AT00961049T AT00961049T ATE315395T1 AT E315395 T1 ATE315395 T1 AT E315395T1 AT 00961049 T AT00961049 T AT 00961049T AT 00961049 T AT00961049 T AT 00961049T AT E315395 T1 ATE315395 T1 AT E315395T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
compositions containing
gastrointestinal tract
acetate compound
improving gastrointestinal
Prior art date
Application number
AT00961049T
Other languages
English (en)
Inventor
Masaaki Nomura
Osamu Sugita
Original Assignee
Daiichi Asubio Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Asubio Pharma Co Ltd filed Critical Daiichi Asubio Pharma Co Ltd
Application granted granted Critical
Publication of ATE315395T1 publication Critical patent/ATE315395T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00961049T 1999-09-17 2000-09-18 Pharmazeutische zusammensetzungen, die faropenem natrium und eine diamineacetat verbindung zur verbesserung der magen-darm trakt absorption enthalten ATE315395T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP26463799 1999-09-17

Publications (1)

Publication Number Publication Date
ATE315395T1 true ATE315395T1 (de) 2006-02-15

Family

ID=17406127

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00961049T ATE315395T1 (de) 1999-09-17 2000-09-18 Pharmazeutische zusammensetzungen, die faropenem natrium und eine diamineacetat verbindung zur verbesserung der magen-darm trakt absorption enthalten

Country Status (11)

Country Link
US (1) US6531508B1 (de)
EP (1) EP1142573B1 (de)
JP (1) JP4745573B2 (de)
KR (1) KR20010101030A (de)
CN (1) CN1198611C (de)
AT (1) ATE315395T1 (de)
CA (1) CA2351673A1 (de)
DE (1) DE60025503T2 (de)
DK (1) DK1142573T3 (de)
ES (1) ES2256035T3 (de)
WO (1) WO2001021175A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025976A1 (es) 1999-10-08 2002-12-26 Affinium Pharm Inc Inhibidores de fab i.
CA2444597A1 (en) * 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
CA2508792C (en) 2002-12-06 2013-02-05 Affinium Pharmaceuticals, Inc. Heterocyclic compounds, methods of making them and their use in therapy
WO2004082586A2 (en) 2003-03-17 2004-09-30 Affinium Pharmaceuticals, Inc. Phamaceutical compositions comprising inhibitors of fab i and further antibiotics
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
CA2568914C (en) * 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
BRPI0615265A8 (pt) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
EP1973902A2 (de) * 2005-12-05 2008-10-01 Affinium Pharmaceuticals, Inc. 3-heterocyclylacrylamidverbindungen als fabi-inhibitoren und antibakterielle mittel
EP2687533B1 (de) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamidderivate als FAB-I-Hemmer
US20090275746A1 (en) * 2006-07-28 2009-11-05 Hetero Drugs Limited Solid faropenem free acid
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
US9169477B2 (en) 2012-01-27 2015-10-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for immunization against bacteria expressing a carbapenemase
SMT201900411T1 (it) 2012-06-19 2019-09-09 Debiopharm Int Sa Derivati di profaramci di (e)-n-metil-n-((3-metilbenzofuran-2-il)metil -3-(7-osso-5,6,7,8-tetraidro-1,8-naftiridin-3-il)acrilammide
BR122023021456A2 (pt) 2016-02-26 2024-02-20 Debiopharm International S.A. Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
FI3923914T3 (fi) 2019-02-14 2023-04-27 Debiopharm Int Sa Afabisiiniformulaatio, menetelmä sen valmistamiseksi
MA56184A (fr) 2019-06-14 2022-04-20 Debiopharm Int Sa Afabicine pour utilisation dans le traitement d'infections bactériennes impliquant un biofilm

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD29756A (de) *
GB909365A (en) * 1960-04-28 1962-10-31 Horner Frank W Ltd Orally ingestible solid penicillin compositions
GB1061426A (en) * 1964-05-22 1967-03-15 Olin Mathieson Water-soluble penicillin composition
US4504485A (en) * 1983-04-04 1985-03-12 Schering Corporation 5R,6S,8R-6-(1-Hydroxyethyl)-2-(2-carbamoyloxyethylthio)-penem-3-carboxylic acid
JP2514249B2 (ja) * 1989-05-23 1996-07-10 帝人株式会社 安定化されたカルシトニン類医薬組成物
ATE217195T1 (de) * 1991-02-01 2002-05-15 Suntory Ltd Verwendung von cilastatin, glutathione und n- acetyl-l-cysteine zur herstellung eines arzneimittels zur verbesserung der resorption von carbapenem oder penem antibiotika im magen-darm- trakt
JPH0769887A (ja) * 1993-07-09 1995-03-14 Takeda Chem Ind Ltd ペネム化合物含有固形組成物、その製造法および剤
JPH0812675A (ja) * 1994-06-30 1996-01-16 Lederle Japan Ltd ２−［（４−ハロゲン置換フェニル）チオ］−カルバペネム誘導体
WO1999036098A1 (en) * 1998-01-13 1999-07-22 Suntory Limited Antibacterial composition for topical administration containing antibiotics

Also Published As

Publication number Publication date
EP1142573A1 (de) 2001-10-10
WO2001021175A1 (fr) 2001-03-29
US6531508B1 (en) 2003-03-11
DE60025503D1 (de) 2006-04-06
KR20010101030A (ko) 2001-11-14
DK1142573T3 (da) 2006-04-10
ES2256035T3 (es) 2006-07-16
EP1142573B1 (de) 2006-01-11
CN1198611C (zh) 2005-04-27
DE60025503T2 (de) 2006-09-07
CN1327385A (zh) 2001-12-19
JP4745573B2 (ja) 2011-08-10
CA2351673A1 (en) 2001-03-29
EP1142573A4 (de) 2002-07-24

Similar Documents

Publication Publication Date Title
DE60025503D1 (de) Pharmazeutische Zusammensetzungen, die Faropenem Natrium und eine Diamineacetat Verbindung zur Verbesserung der Magen-Darm Trakt Absorption enthalten
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
ATE478840T1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
SE0102315D0 (sv) Compounds
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
ATE478841T1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
SE8700499D0 (sv) Novel pharmacologically active compounds
DE59707812D1 (de) Opioidantagonisthaltige galenische formulierung
IL164699A (en) Derivatives of diketohydrazine compounds and pharmaceutical compositions and medicaments containing the compounds as the active ingredient
PT1235799E (pt) Forma polimorfica de atorvastatina-calcio
CA2327723A1 (en) Bicyclic hydroxamic acid derivatives
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
DE60219051D1 (de) Pyrimidonverbindungen und pharmazeutische zusammensetzungen, die diese enthalten
ATE113604T1 (de) Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
DE3686483D1 (de) Arzneimittel.
EP1247456A3 (de) Wohlschmeckende pharmazeutische Zusammensetzung für Haustiere
IL107157A0 (en) Immunopotentiatory agents and pharmaceutical compositions comprising them
DE60134245D1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
WO2004091591A3 (fr) Composition nutritionnelle ou therapeutique contenant le compose oleurofeine ou l'un de ses derives
IL174655A0 (en) Drug containing (2r)-2-propyloctanoic acid as the active ingredient
SE8600658D0 (sv) Novel composition of matter
TWI315308B (en) Compounds with antimicrobial activity and pharmaceutical compositions used as antimicrobial agent
IL174336A0 (en) Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
WO2002028424A3 (en) Kyberdrug as autovaccines with immune-regulating effects
HUP0401862A3 (en) Novel heterocyclic compound and medicinal use thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1142573

Country of ref document: EP

REN Ceased due to non-payment of the annual fee